Which Biologic Medicines Help Crohn's Disease Remission? A 2026 Cochrane Network Review Compares Them All

For people living with Crohn's disease, one of the most consequential conversations with a specialist is about biologic therapy. These medicines can achieve remission when other treatments have not worked, but navigating the options has historically required piecing together separate clinical trials for each individual drug. A 2026 systematic review and network meta-analysis published in the Cochrane Database of Systematic Reviews has taken a different approach, pulling the entire available evidence base into a single comparative analysis (Gordon et al., Cochrane Database Syst Rev, 2026).

What Biologic Therapies Are, and Why They Matter for Crohn's Disease

Crohn's disease is a chronic inflammatory bowel disease that can affect any section of the digestive tract. In many people, it follows a relapsing and remitting course, with periods of active inflammation and periods of remission. The aim of treatment is to achieve and then sustain remission, reducing symptoms, preventing complications, and protecting quality of life.

Biologic therapies are medicines derived from biological sources that target specific components of the immune system involved in Crohn's inflammation. The NHS notes that when conventional medicines such as corticosteroids and immunosuppressants do not provide adequate control of Crohn's disease, biologic therapy may be considered (NHS: Crohn's disease treatment). The biologics available for Crohn's include tumour necrosis factor (TNF) inhibitors such as infliximab and adalimumab; the integrin antagonist vedolizumab; and interleukin inhibitors targeting the IL-12/23 pathway, such as ustekinumab and risankizumab.

What a Network Meta-Analysis Can Tell Us That Individual Trials Cannot

A network meta-analysis is a type of evidence synthesis that allows simultaneous comparison of multiple treatments, including those that have not been directly tested against each other in the same trial. By combining direct comparisons from individual trials with indirect comparisons across the network of available evidence, it can produce estimates of the relative effectiveness of every treatment against every other.

The 2026 Cochrane review applied this method to the full set of available evidence on biologic and advanced therapies for both inducing and maintaining remission in Crohn's disease (Gordon et al., 2026). Cochrane reviews are produced using internationally standardised methods and are widely regarded as the most rigorous form of systematic evidence synthesis.

The significance of a network meta-analysis in this context is that it attempts to answer a question that individual trials are not designed to address: not just "does this treatment work better than placebo?" but "how does this treatment compare to all the other options available?"

Why This Matters for Patients

That comparative question is precisely the one that patients and their gastroenterologists face when considering or reconsidering treatment. Earlier evidence on biologic therapy was fragmented across dozens of separate trials, each comparing a single drug against placebo or a single active comparator. A network meta-analysis synthesises that evidence into a single coherent picture.

For someone with Crohn's disease who has not yet started a biologic, or who is considering whether to switch after an inadequate response, this kind of evidence provides a more complete context for the treatment discussion.

It is important to note that a network meta-analysis provides population-level evidence about average effects. An individual's treatment decision will depend on their specific disease location and behaviour, prior treatment history, other health conditions and medications, and a careful clinical risk-benefit assessment. The NHS advises that treatment choices for Crohn's disease are made collaboratively between the patient and their specialist team (NHS: Crohn's disease treatment).

The Broader Evidence Landscape

Biologic therapy has substantially changed the management of Crohn's disease over the past two decades. Earlier TNF inhibitors established that targeting specific immune pathways could achieve remission in patients who had not responded to conventional treatment. Subsequent approvals of drugs targeting different pathways expanded the range of options further.

A Cochrane network meta-analysis covering the full range of these treatments reflects how significantly the evidence base has grown, and why ongoing engagement with the specialist team remains important for people with Crohn's disease. The study is led by Gordon and colleagues at Cochrane, a research group that has produced multiple systematic reviews on IBD therapeutics, and represents the most current synthesis of comparative evidence available at the time of publication.

This article is an AI-assisted curation of published research. It is not medical advice. If you have Crohn's disease and have questions about biologic therapy, including whether it is appropriate for you or whether a different biologic might be worth considering, speak with your doctor or IBD specialist. They can review your individual disease history and circumstances and discuss the options that may be suitable for you.